CHMP gives green light to generic Keppra, Micardis, Actos and Mirapexin
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Sifrol/Mirapexin (pramipexole) and Micardis (telmisartan), UCB's Keppra (levetiracetam) and Takeda's Actos (pioglitazone) are set to face greater generic competition after the European Medicine's agency's scientific committee , the CHMP, today announced a raft of positive opinions for generic medicines.